Idenix sees delay in hep c drug human trials as FDA seeks more data

(Reuters) – Idenix Pharmaceuticals Inc said it expects a delay in human trials of one of its experimental hepatitis C drugs after the U.S. Food and Drug Administration asked for additional safety data, sending its shares down 30 percent after the bell. Clinical trials of the drug, codenamed IDX20963, has been put on hold until it provides a satisfactory response to the FDA, Idenix said in a statement. Hepatitis C is an disease that affects the liver and if left untreated can lead to cirrhosis, cancer or need for a transplant. …